About ColoVantage®

WATCH

DIAGNOSTIC ADVANCES IN COLORECTAL CANCER SCREENING


To leave this site and access a CME activity on colorectal cancer sponsored by, but developed independently of Quest Diagnostics:

GO >

ColoVantage® is a convenient blood test that aids in the detection of colorectal cancer in patients non-adherent to current testing approaches.

This test detects methylated Septin9 DNA, a proven marker of the presence of colorectal cancer that has been validated in multiple studies. In a clinical validation study, ColoVantage achieved an overall 70% sensitivity and 89% specificity.1

ColoVantage has successfully detected cancer at all stages. Patients who test positive for methylated Septin9 should be further evaluated for the presence of colorectal cancer.

Unique Option to Help Detect Colorectal Cancer

Colorectal cancer treated in localized, early stages has a five-year survival rate of 90 percent2. Yet, only 40 percent of cases3 are diagnosed in early stages, due to low screening rates.

Colonoscopy, the "gold standard" for colorectal cancer screening, has >95% sensitivity and 90% specificity4 and should be offered first when medically possible. However, approximately half of all Americans aged 50 and over5 do not have any colorectal cancer screening. Patients resist or delay colonoscopy most often because of: unpleasant preparation, economic challenges, fear of pain, procedural risk, embarrassment and concerns about anesthesia.

Fecal tests are an option for patients unable or unwilling to do colonoscopy and are recommended yearly for screening eligible patients. These tests have a sensitivity range of 56% to 91% and specificity of 83% to 98%6. Patients also resist these tests due to unpleasant specimen collection.

ColoVantage does not require any dietary restrictions or special patient preparation and can be added to routine blood work. The blood can be drawn at any time of day.

You can order this test through Quest Diagnostics using test code 16983(X).

References

  1. Data on file at Quest Diagnostics.
  2. Altekruse SF, Kosary CL,, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2007. National Cancer Institute SEER Web site. http://seer.cancer.gov/csr/1975_2007/sections.html. Updated June 30, 2010. Accessed January 24, 2011.
  3. American Cancer Society. Statistics for 2010. American Cancer Society Web site. http://www.cancer.org/Research/CancerFactsFigures/index. Accessed January 24, 2011.
  4. Lieberman DA. N Engl J Med 2009;361:1179-87
  5. Shapiro JA, Seeff LC, Thompson TD, et al. Colorectal cancer test use from the 2005 national health interview survey. Cancer Epidemiol Biomarkers Prev. 2008;17:1623-1630.
  6. Whitlock et al. Rev Scr tests for CRC Ann Intern Med 2009